„Regarding the search for partners we looked at some research institutions, of course also in the US, but RCPE gave us the technologies and the know-how required for a long-term cooperation,“ said Dr. Klaus Nickisch, Chief Science Officer & Executive Vice President of Evestra in 2014. The fact that until today nothing has changed his position and confidence in the Styrian center, is reflected in the renewal of the contract with the research company.
The core of the cooperation is located in the field of women’s health; a central theme is the realization of next-generation vaginal dosage forms. Specifically working on the development and advancement of specific vaginal rings for contraception, hormone replacement therapy, incontinence and combined preparations. „In the first years of cooperation, we have already achieved a lot of expertise in the field of „Female Health“. Specifically, the current project aims to establish a platform technology for the production of vaginal dosage forms based on fundamental scientific principles.“ explains Prof. Khinast, Scientific Director of RCPE.
Besides the establishment of screening methods, simulation-based predictions of drug release and the establishment of a bio-relevant release method, the focus is in the development of process technology optimized production processes in the field of pharmaceutical polymer processing. The thus constructed methods and techniques are then applied to the development pipeline of Evestra. This should allow to evaluate product ideas safer, faster and more cost-effective and bring about a more rapid market entry.
The advantages for the end user are clear. In the future new vaginal dosage forms with precise drug delivery in the therapeutic range shall be available. Different to preparations intended for oral administration, clear advantages are shown. The drug acts targeted and stable over a longer period. At the same time, it is prevented that, as by oral intake caused by ingestion, errors or gastrointestinal diseases create complete or partial absorption failures of active ingredients. As the active ingredients are released directly in the female sexual organ, low dosages that cause less harm to the body are sufficient. Possible side effects are reduced or avoided.
For RCPE, which is owned by Graz University of Technology, the University of Graz and the Joanneum Research, it’s not the first contract of this magnitude. „Research jobs like these allow us to expand our expertise and to strengthen the unique position of RCPE in the field of pharmaceutical process and product optimization. The long-term partnership with Evestra enables to build highly qualified staff within the region.”, mentions Dr. Klein, Business Director at RCPE.
Information about the company
Together with the global players in the pharmaceutical industry the K1 Competence Centre RCPE conducts cutting-edge research in the field of process and product optimization. The priorities include the development of new drug delivery systems, the associated production processes and their monitoring. In addition to an experienced multidisciplinary and international team the outstanding achievements of the center are due to its proximity to the universities of Graz. As link between science and industry RCPE offers industrial research on state of the art. RCPE is owned by Graz University of Technology (65%), the KF University Graz (20%) and the Joanneum Research GmbH (15%).
The Texan pharmaceutical company Evestra headquartered in San Antonio was founded in 2007 as a spin-off of the Organic Chemistry Department of Texas Biomedical Research Institute of Ze’ev Shaked and Klaus Nickisch, both long-standing experienced in the field of pharmaceutical product development. Klaus Nickisch specializes as Scientific Director on the topics oncology and women’s health. Evestra performs research and product development through in a number of important areas such as in the field of women’s health. Additionally, to contraception the issues are endometriosis, uterine fibroids, hormone replacement therapy or hormone-dependent breast cancer.